Akero Therapeutics may not have adequate data for accelerated approval of its MASH drug, despite showing it may reverse ...

NEW YORK CITY, NY / ACCESS Newswire / March 23, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

Shares of NASDAQ AKRO opened at $45.24 on Wednesday. Akero Therapeutics, Inc. has a fifty-two week low of $17.86 and a fifty-two week high of $58.40. The company has a debt-to-equity ratio of 0.05 ...

18.4% of Rezolute shares are held by insiders. Comparatively, 7.9% of Akero Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds ...

In this article, we are going to take a look at where Akero Therapeutics, Inc. (NASDAQ:AKRO) stands against the other biotech stocks. No matter the market environment, you’ll always find ...

Feb. 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by ...

Cargo was founded by two highly acclaimed cell-therapy researchers. The company raised over $500 million to develop ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor ...